Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 2 | 8 |
| 1.1 List of Tables | 6 | 3 |
| 1.2 List of Figures | 9 | 1 |
| 2 Introduction | 10 | 1 |
| 2.1 Melanoma Diagnostic Tests Overview | 10 | 1 |
| 3 Products under Development | 11 | 5 |
| 3.1 Melanoma Diagnostic Tests - Pipeline Products by Stage of Development | 11 | 1 |
| 3.2 Melanoma Diagnostic Tests - Pipeline Products by Territory | 12 | 1 |
| 3.3 Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path | 13 | 1 |
| 3.4 Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date | 14 | 1 |
| 3.5 Melanoma Diagnostic Tests - Ongoing Clinical Trials | 15 | 1 |
| 4 Melanoma Diagnostic Tests - Pipeline Products under Development by Companies | 16 | 4 |
| 4.1 Melanoma Diagnostic Tests Companies - Pipeline Products by Stage of Development | 16 | 2 |
| 4.2 Melanoma Diagnostic Tests - Pipeline Products by Stage of Development | 18 | 2 |
| 5 Melanoma Diagnostic Tests Companies and Product Overview | 20 | 59 |
| 5.1 Abbott Diagnostics Company Overview | 20 | 1 |
| 5.1.1 Abbott Diagnostics Pipeline Products &Ongoing Clinical Trials Overview | 20 | 2 |
| 5.2 Adaptive Biotechnologies Corporation Company Overview | 22 | 1 |
| 5.2.1 Adaptive Biotechnologies Corporation Pipeline Products &Ongoing Clinical Trials Overview | 22 | 1 |
| 5.3 Agilent Technologies, Inc. Company Overview | 23 | 1 |
| 5.3.1 Agilent Technologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 23 | 2 |
| 5.4 BioMark Diagnostics Inc. Company Overview | 25 | 1 |
| 5.4.1 BioMark Diagnostics Inc. Pipeline Products &Ongoing Clinical Trials Overview | 25 | 1 |
| 5.5 BioMarker Strategies, LLC Company Overview | 26 | 1 |
| 5.5.1 BioMarker Strategies, LLC Pipeline Products &Ongoing Clinical Trials Overview | 26 | 2 |
| 5.6 Biosceptre (Aust) Pty Ltd Company Overview | 28 | 1 |
| 5.6.1 Biosceptre (Aust) Pty Ltd Pipeline Products &Ongoing Clinical Trials Overview | 28 | 1 |
| 5.7 Bio-Techne Corp Company Overview | 29 | 1 |
| 5.7.1 Bio-Techne Corp Pipeline Products &Ongoing Clinical Trials Overview | 29 | 2 |
| 5.8 Boston University Company Overview | 31 | 1 |
| 5.8.1 Boston University Pipeline Products &Ongoing Clinical Trials Overview | 31 | 1 |
| 5.9 Ceres Nanosciences, Inc. Company Overview | 32 | 1 |
| 5.9.1 Ceres Nanosciences, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 32 | 1 |
| 5.10 Dana-Farber Cancer Institute, Inc. Company Overview | 33 | 1 |
| 5.10.1 Dana-Farber Cancer Institute, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 33 | 1 |
| 5.11 Digna Biotech, S.L. Company Overview | 34 | 1 |
| 5.11.1 Digna Biotech, S.L. Pipeline Products &Ongoing Clinical Trials Overview | 34 | 1 |
| 5.12 Exosomics Siena SpA Company Overview | 35 | 1 |
| 5.12.1 Exosomics Siena SpA Pipeline Products &Ongoing Clinical Trials Overview | 35 | 1 |
| 5.13 Genentech, Inc. Company Overview | 36 | 1 |
| 5.13.1 Genentech, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 36 | 1 |
| 5.14 Genomic Health, Inc. Company Overview | 37 | 1 |
| 5.14.1 Genomic Health, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 37 | 2 |
| 5.15 Hospital Universitario Cruces Company Overview | 39 | 1 |
| 5.15.1 Hospital Universitario Cruces Pipeline Products &Ongoing Clinical Trials Overview | 39 | 1 |
| 5.16 Hummingbird Diagnostics GmbH Company Overview | 40 | 1 |
| 5.16.1 Hummingbird Diagnostics GmbH Pipeline Products &Ongoing Clinical Trials Overview | 40 | 1 |
| 5.17 ImmunID Company Overview | 41 | 1 |
| 5.17.1 ImmunID Pipeline Products &Ongoing Clinical Trials Overview | 41 | 4 |
| 5.18 Institut Pasteur Company Overview | 45 | 1 |
| 5.18.1 Institut Pasteur Pipeline Products &Ongoing Clinical Trials Overview | 45 | 1 |
| 5.19 InterGenetics Incorporated Company Overview | 46 | 1 |
| 5.19.1 InterGenetics Incorporated Pipeline Products &Ongoing Clinical Trials Overview | 46 | 1 |
| 5.20 IV Diagnostics, Inc. Company Overview | 47 | 1 |
| 5.20.1 IV Diagnostics, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 47 | 1 |
| 5.21 John Hopkins University Company Overview | 48 | 1 |
| 5.21.1 John Hopkins University Pipeline Products &Ongoing Clinical Trials Overview | 48 | 1 |
| 5.22 Louisville Bioscience, Inc. Company Overview | 49 | 1 |
| 5.22.1 Louisville Bioscience, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 49 | 1 |
| 5.23 MDNA Life Sciences, Inc. Company Overview | 50 | 1 |
| 5.23.1 MDNA Life Sciences, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 50 | 1 |
| 5.24 Melanovus Oncology, Inc. Company Overview | 51 | 1 |
| 5.24.1 Melanovus Oncology, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 51 | 1 |
| 5.25 Memorial Sloan Kettering Cancer Center Company Overview | 52 | 1 |
| 5.25.1 Memorial Sloan Kettering Cancer Center Pipeline Products &Ongoing Clinical Trials Overview | 52 | 1 |
| 5.26 MyCardio,LLC. Company Overview | 53 | 1 |
| 5.26.1 MyCardio,LLC. Pipeline Products &Ongoing Clinical Trials Overview | 53 | 1 |
| 5.27 Myriad Genetics, Inc. Company Overview | 54 | 1 |
| 5.27.1 Myriad Genetics, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 54 | 2 |
| 5.28 Orion Genomics LLC Company Overview | 56 | 1 |
| 5.28.1 Orion Genomics LLC Pipeline Products &Ongoing Clinical Trials Overview | 56 | 1 |
| 5.29 Oryzon Genomics SA Company Overview | 57 | 1 |
| 5.29.1 Oryzon Genomics SA Pipeline Products &Ongoing Clinical Trials Overview | 57 | 2 |
| 5.30 Pacific Edge Limited Company Overview | 59 | 1 |
| 5.30.1 Pacific Edge Limited Pipeline Products &Ongoing Clinical Trials Overview | 59 | 2 |
| 5.31 Protea Biosciences Group, Inc. Company Overview | 61 | 1 |
| 5.31.1 Protea Biosciences Group, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 61 | 2 |
| 5.32 Qiagen N.V. Company Overview | 63 | 1 |
| 5.32.1 Qiagen N.V. Pipeline Products &Ongoing Clinical Trials Overview | 63 | 2 |
| 5.33 Roche Diagnostics International Ltd. Company Overview | 65 | 1 |
| 5.33.1 Roche Diagnostics International Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 65 | 4 |
| 5.34 Rosetta Genomics Ltd Company Overview | 69 | 1 |
| 5.34.1 Rosetta Genomics Ltd Pipeline Products &Ongoing Clinical Trials Overview | 69 | 2 |
| 5.35 Sividon Diagnostics GmbH Company Overview | 71 | 1 |
| 5.35.1 Sividon Diagnostics GmbH Pipeline Products &Ongoing Clinical Trials Overview | 71 | 1 |
| 5.36 SomaLogic, Inc. Company Overview | 72 | 1 |
| 5.36.1 SomaLogic, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 72 | 1 |
| 5.37 University of California, San Francisco Company Overview | 73 | 1 |
| 5.37.1 University of California, San Francisco Pipeline Products &Ongoing Clinical Trials Overview | 73 | 1 |
| 5.38 University of Colorado Company Overview | 74 | 1 |
| 5.38.1 University of Colorado Pipeline Products &Ongoing Clinical Trials Overview | 74 | 1 |
| 5.39 University of Louisville Company Overview | 75 | 1 |
| 5.39.1 University of Louisville Pipeline Products &Ongoing Clinical Trials Overview | 75 | 1 |
| 5.40 University of Maryland, Baltimore Company Overview | 76 | 1 |
| 5.40.1 University of Maryland, Baltimore Pipeline Products &Ongoing Clinical Trials Overview | 76 | 1 |
| 5.41 Vanderbilt University Company Overview | 77 | 1 |
| 5.41.1 Vanderbilt University Pipeline Products &Ongoing Clinical Trials Overview | 77 | 1 |
| 5.42 Zymera, Inc Company Overview | 78 | 1 |
| 5.42.1 Zymera, Inc Pipeline Products &Ongoing Clinical Trials Overview | 78 | 1 |
| 6 Melanoma Diagnostic Tests - Recent Developments | 79 | 52 |
| 6.1 Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare | 79 | 1 |
| 6.2 Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy | 79 | 1 |
| 6.3 Sep 26, 2016: Rosetta Genomics Reports 2016 Second Quarter Financial Results | 80 | 2 |
| 6.4 Sep 20, 2016: Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline | 82 | 1 |
| 6.5 Sep 15, 2016: Agilent Technologies Raises USD300 Million in Public Offering of Notes Due 2026 | 82 | 1 |
| 6.6 Sep 01, 2016: Novel Test Distinguishes Atypical Moles From Melanoma | 82 | 1 |
| 6.7 Aug 31, 2016: bioMerieux - First-Half 2016 Results | 83 | 4 |
| 6.8 Aug 29, 2016: Dr. Ann Hanham Joins HTG Molecular Diagnostics Board of Directors | 87 | 1 |
| 6.9 Aug 17, 2016: Agilent Technologies Reports Third-Quarter 2016 Results | 87 | 1 |
| 6.10 Aug 16, 2016: Protea Announces Second Quarter 2016 Results | 88 | 1 |
| 6.11 Aug 09, 2016: Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results | 89 | 1 |
| 6.12 Aug 09, 2016: HTG Molecular Diagnostics Reports Second Quarter 2016 Results | 90 | 1 |
| 6.13 Aug 08, 2016: Oryzon Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016 | 91 | 1 |
| 6.14 Aug 02, 2016: Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance | 91 | 2 |
| 6.15 Jul 28, 2016: QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017 | 93 | 3 |
| 6.16 Jul 27, 2016: GSK announces significant new investment in UK manufacturing network | 96 | 1 |
| 6.17 Jul 27, 2016: GlaxoSmithKline: Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016 | 97 | 16 |
| 6.18 Jul 21, 2016: Quest Diagnostics Reports Second Quarter 2016 Financial Results | 113 | 1 |
| 6.19 Jul 18, 2016: bioMerieux Second-Quarter 2016 Business Review | 114 | 3 |
| 6.20 Jul 07, 2016: GSK and Save the Children call for developing country innovations to enter $1 million award | 117 | 1 |
| 6.21 Jul 06, 2016: Bio-Techne Acquires Advanced Cell Diagnostics | 118 | 1 |
| 6.22 Jul 05, 2016: MolecularMD Raises USD0.5 Million in Venture Financing | 118 | 1 |
| 6.23 Jul 04, 2016: Exiqon Nomination of candidates for the supervisory board | 118 | 1 |
| 6.24 Jun 23, 2016: HTG Molecular Diagnostics Announces VERI/O Laboratory Service | 118 | 1 |
| 6.25 Jun 20, 2016: HTG Molecular Appoints New Vice President of North American Capital Sales for the HTG EdgeSeq Platform | 119 | 1 |
| 6.26 Jun 15, 2016: Quest Diagnostics and Safeway Team to Offer Convenient Diagnostic Testing to Customers in More States | 119 | 1 |
| 6.27 Jun 14, 2016: GlaxoSmithKline: Executive Director Change | 120 | 1 |
| 6.28 Jun 02, 2016: Pacific Edge Board Changes Announced | 120 | 1 |
| 6.29 May 31, 2016: Myriad Genetics Acquires Sividon Diagnostics | 121 | 1 |
| 6.30 May 31, 2016: Quest Diagnostics and HCA's HealthONE System Partner to Deliver High-Value and Innovative Laboratory Services at Six Denver-Area HealthONE Hospitals | 121 | 1 |
| 6.31 May 27, 2016: Protea Biosciences to Raise Funds through Public Offering of Shares | 121 | 1 |
| 6.32 May 23, 2016: Quest Diagnostics Raises USD500 Million in Public Offering of 3.45% Senior Notes due 2026 | 121 | 1 |
| 6.33 May 20, 2016: International Comparison of BRAF Testing in Melanoma Abstract Released in Conjunction With ASCO 2016 | 122 | 1 |
| 6.34 May 20, 2016: Avalon Ventures and COI Pharmaceuticals Announce First Milestones for Sitari Pharmaceuticals and Silarus Therapeutics and Formation of Eighth Company | 122 | 1 |
| 6.35 May 16, 2016: Agilent Technologies Reports Second-Quarter 2016 Results | 123 | 1 |
| 6.36 May 16, 2016: Protea Announces First Quarter 2016 Results | 124 | 1 |
| 6.37 May 12, 2016: Oryzon Reports First Quarter 2016 Financial Results and Corporate Update | 124 | 1 |
| 6.38 May 12, 2016: HTG Molecular Diagnostics Reports First Quarter 2016 Results | 125 | 1 |
| 6.39 May 11, 2016: Dako, an Agilent Technologies Company, Announces Expanded Use of PD-L1 Diagnostic Test in Europe | 125 | 1 |
| 6.40 Apr 25, 2016: Protea Biosciences Enters into Licensing Agreement with Yale University | 126 | 1 |
| 6.41 Mar 31, 2016: ImmunTraCkeR Results on Prediction of Response to Cancer Immunotherapy Selected for Presentation at ASCO Annual Meeting | 126 | 1 |
| 6.42 Mar 15, 2016: Myriad Presents Second Pivotal Validation Study for Its myPath Melanoma Test | 126 | 1 |
| 6.43 Feb 23, 2016: ImmunID Signs Master Collaboration Agreement with MSK about the Prediction of Response to Immuno-Oncology Agents Using ImmunTraCkeR | 127 | 1 |
| 6.44 Feb 15, 2016: Collaboration led by ImmunID Awarded Innovate UK Grant to Advance Program on Prediction of Response to Cancer Immunotherapy using ImmunTraCkeR | 128 | 1 |
| 6.45 Jan 25, 2016: Quest Diagnostics Expands Dako's PD-L1 IHC 28-8 Complementary Test to Include Melanoma | 128 | 1 |
| 6.46 Jan 25, 2016: Dako, an Agilent Technologies Company, Announces Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma | 129 | 1 |
| 6.47 Jan 11, 2016: Blood Test that Monitors Dead Cancer Cell DNA Better at Tracking Spread of Melanoma | 130 | 1 |
| 7 Appendix | 131 | 4 |
| 7.1 Methodology | 131 | 2 |
| 7.2 About GlobalData | 133 | 1 |
| 7.3 Contact Us | 133 | 1 |
| 7.4 Disclaimer | 134 | 1 |